Cediranib

250px
Cediranib
Systematic (IUPAC) name
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- 7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	C25H27FN4O3
Mol. mass	450.5 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	12 to 35 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

WikiDoc Resources for Cediranib
Articles
Most recent articles on Cediranib Most cited articles on Cediranib Review articles on Cediranib Articles on Cediranib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cediranib Images of Cediranib Photos of Cediranib Podcasts & MP3s on Cediranib Videos on Cediranib
Evidence Based Medicine
Cochrane Collaboration on Cediranib Bandolier on Cediranib TRIP on Cediranib
Clinical Trials
Ongoing Trials on Cediranib at Clinical Trials.gov Trial results on Cediranib Clinical Trials on Cediranib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cediranib NICE Guidance on Cediranib NHS PRODIGY Guidance FDA on Cediranib CDC on Cediranib
Books
Books on Cediranib
News
Cediranib in the news Be alerted to news on Cediranib News trends on Cediranib
Commentary
Blogs on Cediranib
Definitions
Definitions of Cediranib
Patient Resources / Community
Patient resources on Cediranib Discussion groups on Cediranib Patient Handouts on Cediranib Directions to Hospitals Treating Cediranib Risk calculators and risk factors for Cediranib
Healthcare Provider Resources
Symptoms of Cediranib Causes & Risk Factors for Cediranib Diagnostic studies for Cediranib Treatment of Cediranib
Continuing Medical Education (CME)
CME Programs on Cediranib
International
Cediranib en Espanol Cediranib en Francais
Business
Cediranib in the Marketplace Patents on Cediranib
Experimental / Informatics
List of terms related to Cediranib

Overview

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

Further reading

• Wedge S, Kendrew J, Hennequin L et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res 65 (10): 4389–400. PMID 15899831.

External links

• AZD2171—AstraZeneca Pipeline